For people with bleeding disorders (PWBDs), any serious injury can be life-threatening. This is especially true of children. In Cuba, an 8-year-old boy with mild hemophilia A was involved in an accident which caused a hematoma in his leg. This simple condition could have had serious consequences for the child if it wasn’t for donated factor provided by the WFH Humanitarian Aid Program. The donations immediately improved his condition, and his mother was provided with more factor to bring to their home near Havana to ensure that he could recover fully.
The WFH Humanitarian Aid Program provided over 700,000 IUs donated factor to hemophilia treatment centres (HTCs) in Cuba last year—despite logistics challenges created by COVID-19. To find out more about the WFH Humanitarian Aid Program, please click here.
About the WFH Humanitarian Aid Program
The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi Genzyme and Sobi, our Founding Visionary Contributors; Bayer and Roche, our Visionary Contributors; Grifols, our Leadership Contributor; and our Contributors, CSL Behring and Takeda. To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org.